Clinical Trial Update: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring mechanisms of action and neuroprotective potential of alemtuzumab in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: University Hospital Muenster | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED